Monitoring soluble CD146 levels in glioblastoma patients treated with bevacizumab

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to prospectively monitor the levels of soluble CD146 in the plasma of patients with recurrent glioblastoma who are being treated with the anti-VEGF antibody bevacizumab. Patients will have plasma samples collected at various points: before the first and second bevacizumab administrations, at the time of the first MRI evaluation, and at disease progression. The goal is to analyze the correlation between soluble CD146 levels and patient outcomes, particularly in relation to resistance to bevacizumab treatment.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* \- Adult patients with recurrent IDHwt glioblastoma
* Relapse after standard first line treatment (radio-chemotherapy)
* Candidate for bevacizumab treatment
* Able to be monitored by MRI
* KPS ≥ 60%
* Written signed consent form

Exclusion Criteria:

* Pregnancy or breast feeding
* Life expectancy less than 3 months
* Bevacizumab in first line treatment
* Other concomitant life-threatening disease
* Under legal protection

Where it's running

• Service de Neuro-oncologie
  Marseille, France Recruiting

Study contacts

• Principal investigator: Emeline Tabouret — Ap-Hm
• Study coordinator: Emeline Tabouret
• Email: emeline.tabouret@ap-hm.fr
• Phone: 0491385500

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Trimipramine with atezolizumab and bevacizumab for recurrent glioblastoma

  Researchers will try whether adding the antidepressant trimipramine to the immunotherapy atezolizumab plus bevacizumab helps people with recurrent glioblastoma.

  Recruiting at 7 sites Phase 2 Centre Hospitalier Universitaire Vaudois · Basel, Basel and 6 other locations · NCT07263438

• PSMA PET/CT for GBM patients on bevacizumab

  This study tests PSMA PET/CT scans in adults with IDH-wildtype glioblastoma who are receiving bevacizumab to see how PSMA expression relates to VEGF in their tumors.

  Recruiting Royal North Shore Hospital · Saint Leonards, New South Wales · NCT07052877

• Evaluating Bevacizumab with Focused Ultrasound for Recurrent Glioblastoma

  This study is testing if adding focused ultrasound to the standard treatment of Bevacizumab can help people with recurrent glioblastoma feel better and live longer.

  Recruiting at 2 sites Phase 3 NaviFUS Corporation · Taipei and 1 other locations · NCT06496971

• Infusion of Bevacizumab with Chemotherapy and Radiation for Newly Diagnosed Glioblastoma

  This study is testing if adding a special infusion of Bevacizumab to standard chemotherapy and radiation can help people with newly diagnosed glioblastoma live longer and feel better.

  Recruiting Phase 3 Northwell Health · New York, New York · NCT05271240

• Biomarkers to predict 6‑month survival with Avastin in first‑relapse glioblastoma

  This project will test whether early MRI spectroscopy markers can predict which people with first‑relapse glioblastoma treated with Avastin will live six months or longer.

  Recruiting Centre Hospitalier Universitaire, Amiens · Amiens, Picardie · NCT03144167

• YN003 injection in glioma patients

  This phase 1 study tests whether YN003 injected IV is safe and tolerable for adults with recurrent or progressive glioma, and to explore how the drug behaves in the body and any early signs of activity.

  Recruiting at 2 sites Phase 1 Beijing Inno Medicine Co., Ltd. · Los Angeles, California and 4 other locations · NCT07929909

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.